

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2009-01-26** | Period of Report: **2009-01-22**

SEC Accession No. **0000950117-09-000122**

([HTML Version](#) on secdatabase.com)

ISSUER

SAVIENT PHARMACEUTICALS INC

CIK: **722104** | IRS No.: **133033811** | State of Incorporation: **DE** | Fiscal Year End: **1231**
SIC: **2833** Medicinal chemicals & botanical products

Mailing Address

*ONE TOWER CENTER
EAST BRUNSWICK NJ 08816*

Business Address

*ONE TOWER CENTER
EAST BRUNSWICK NJ 08816
7324189300*

REPORTING OWNER

Lamm Robert

CIK: **1354440**
Type: **4** | Act: **34** | File No.: **000-15313** | Film No.: **09545721**

Mailing Address

*C/O SAVIENT
PHARMACEUTICALS, INC.
ONE TOWER CENTER BLVD.,
14TH FLOOR
EAST BRUNSWICK NJ 08816*

Business Address

732-418-9300

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: 02/28/2011
 Estimated average burden
 hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Lamm Robert			2. Issuer Name and Ticker or Trading Symbol SAVIENT PHARMACEUTICALS INC [SVNT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) SVP, Quality & Reg. Affairs		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/22/2009			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
C/O SAVIENT PHARMACEUTICALS, INC, ONE TOWER CENTER BLVD, 14TH FLOOR			4. If Amendment, Date Original Filed(Month/Day/Year)					
(Street) EAST BRUNSWICK, NJ 08816								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.1 par value per share	01/22/2009		S ⁽¹⁾		2,230	D	\$6.1015	48,862	D	
Common Stock, \$0.1 par value per share	08/31/2008		A ⁽²⁾	V	967	A	\$11.3475	49,829	D	
Common Stock, \$0.1 par value per share	02/29/2008		A ⁽²⁾		905	A	\$11.3475	50,734	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

1. These shares were sold automatically pursuant to a binding contract under Rule 10b5-1 of the Securities Exchange Act of 1934, to cover tax withholding obligations in connection with the vesting of restricted stock granted on January 21, 2005.
2. Consists of shares acquired pursuant to the Savient Pharmaceuticals, Inc. 1998 Employee Stock Purchase Plan, which were not previously reported on a Form 4.

Signatures

By: /s/ Irina Azer as Attorney-In-Fact for

** Signature of Reporting Person

01/26/2009

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.